Loading...

genOway

DB:JEH
Snowflake Description

Fair value with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
JEH
DB
€10M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

genOway S.A., a biotechnology company, engages in the development and sale of custom genetically-modified mouse, rat, and cellular models worldwide. The last earnings update was 27 days ago. More info.


Add to Portfolio Compare Print
  • genOway has significant price volatility in the past 3 months.
JEH Share Price and Events
7 Day Returns
0%
DB:JEH
-0.1%
DE Biotechs
1%
DE Market
1 Year Returns
1.4%
DB:JEH
-7.4%
DE Biotechs
-5.6%
DE Market
JEH Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
genOway (JEH) 0% -24.6% -22.3% 1.4% 12% -24%
DE Biotechs -0.1% 6% -6.7% -7.4% 53.2% 11.6%
DE Market 1% 6.1% 8.4% -5.6% 10.9% 13.8%
1 Year Return vs Industry and Market
  • JEH outperformed the Biotechs industry which returned -7.4% over the past year.
  • JEH outperformed the Market in Germany which returned -5.6% over the past year.
Price Volatility
JEH
Industry
5yr Volatility vs Market

Value

 Is genOway undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for genOway. This is due to cash flow or dividend data being unavailable. The share price is €1.78.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for genOway's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are genOway's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:JEH PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in EUR €0.11
ENXTPA:ALGEN Share Price ** ENXTPA (2019-04-24) in EUR €1.74
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.73x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.72x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of genOway.

DB:JEH PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:ALGEN Share Price ÷ EPS (both in EUR)

= 1.74 ÷ 0.11

15.33x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • genOway is good value based on earnings compared to the Europe Biotechs industry average.
  • genOway is good value based on earnings compared to the Germany market.
Price based on expected Growth
Does genOway's expected growth come at a high price?
Raw Data
DB:JEH PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 15.33x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
25.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for genOway, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on genOway's assets?
Raw Data
DB:JEH PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in EUR €1.31
ENXTPA:ALGEN Share Price * ENXTPA (2019-04-24) in EUR €1.74
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.72x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:JEH PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:ALGEN Share Price ÷ Book Value per Share (both in EUR)

= 1.74 ÷ 1.31

1.33x

* Primary Listing of genOway.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • genOway is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess genOway's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. genOway has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is genOway expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

  • No analysts cover genOway, future earnings growth has been estimated based on fundamentals.
The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
25.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is genOway expected to grow at an attractive rate?
  • genOway's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • genOway's earnings growth is expected to exceed the Germany market average.
  • Unable to compare genOway's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:JEH Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:JEH Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts 25.3%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:JEH Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:JEH Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-12-31 15 1
2018-09-30 14 1
2018-06-30 13 1
2018-03-31 13 1
2017-12-31 13 2
2017-09-30 13 2
2017-06-30 13 1 2
2017-03-31 12 0 1
2016-12-31 12 -1 1
2016-09-30 11 0
2016-06-30 10 0 0
2016-03-31 10 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • genOway's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if genOway is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:JEH Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from genOway Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:JEH Past Financials Data
Date (Data in EUR Millions) EPS *
2018-12-31
2018-09-30
2018-06-30 0.11
2018-03-31 0.23
2017-12-31 0.32
2017-09-30 0.33
2017-06-30
2017-03-31
2016-12-31 0.10
2016-09-30 0.07
2016-06-30
2016-03-31

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if genOway will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess genOway's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
genOway has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has genOway performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare genOway's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • genOway has delivered over 20% year on year earnings growth in the past 5 years.
  • genOway's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • genOway's 1-year earnings growth is negative, it can't be compared to the Europe Biotechs industry average.
Earnings and Revenue History
genOway's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from genOway Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:JEH Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 14.80 0.57
2018-09-30 13.65 0.61 2.71
2018-06-30 12.75 0.65 5.42
2018-03-31 12.74 1.29 5.32
2017-12-31 12.73 1.93 5.21
2017-09-30 12.92 1.97 5.24
2017-06-30 12.87 2.00 5.26
2017-03-31 12.21 1.29 5.02
2016-12-31 11.54 0.58 4.78
2016-09-30 10.91 0.39 4.63
2016-06-30 10.27 0.20 4.48
2016-03-31 10.20 0.12 4.42
2015-12-31 10.13 0.04 4.36
2015-09-30 10.05 0.02 4.27
2015-06-30 9.96 0.00 4.18
2015-03-31 9.80 0.01 4.20
2014-12-31 9.63 0.03 4.22
2014-09-30 9.64 0.12 4.22
2014-06-30 9.65 0.21 4.22
2014-03-31 9.75 0.23 4.16
2013-12-31 9.85 0.26 4.10
2013-09-30 9.60 0.21 4.05
2013-06-30 9.35 0.16 4.01
2013-03-31 8.96 -0.10 3.88
2012-12-31 8.58 -0.35 3.74
2012-09-30 8.53 -0.25 3.60
2012-06-30 8.49 -0.15 3.46

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • genOway has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • genOway used its assets less efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • genOway's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess genOway's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
genOway has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is genOway's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up genOway's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • genOway is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • genOway's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of genOway's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 2.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from genOway Company Filings, last reported 3 months ago.

DB:JEH Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31
2018-09-30 7.51 4.78 1.51
2018-06-30 7.51 4.78 1.51
2018-03-31 7.51 4.78 1.51
2017-12-31 7.19 3.74 3.95
2017-09-30 7.19 3.74 3.95
2017-06-30 6.86 3.60 2.36
2017-03-31 6.86 3.60 2.36
2016-12-31 5.26 0.01 2.64
2016-09-30 5.26 0.01 2.64
2016-06-30 4.86 0.01 2.37
2016-03-31 4.86 0.01 2.37
2015-12-31 4.68 0.01 3.79
2015-09-30 4.68 0.01 3.79
2015-06-30 4.71 0.01 2.93
2015-03-31 4.71 0.01 2.93
2014-12-31 5.15 0.21 3.82
2014-09-30 5.15 0.21 3.82
2014-06-30 5.17 0.07 3.68
2014-03-31 5.17 0.07 3.68
2013-12-31 4.99 0.01 4.55
2013-09-30 4.99 0.01 4.55
2013-06-30 5.00 0.01 4.05
2013-03-31 5.00 0.01 4.05
2012-12-31 4.84 0.04 4.01
2012-09-30 4.84 0.04 4.01
2012-06-30 4.82 0.01 5.31
  • genOway's level of debt (63.6%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0.1% vs 63.6% today).
  • Unable to verify if debt is well covered by operating cash flow as genOway has not reported sufficient balance sheet data.
  • Interest payments on debt are well covered by earnings (EBIT is 3.6x coverage).
X
Financial health checks
We assess genOway's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. genOway has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is genOway's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from genOway dividends.
If you bought €2,000 of genOway shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate genOway's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate genOway's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:JEH Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as genOway has not reported any payouts.
  • Unable to verify if genOway's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of genOway's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as genOway has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess genOway's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can genOway afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. genOway has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of genOway's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Alexandre Fraichard
TENURE AS CEO 0.3 years
CEO Bio

Dr. Alexandre Fraichard, MBA, HEC, Co-Founded GenOway S.A. in 1999 and also has been its Chief Executive Officer since 2019. Dr. Fraichard had been General Manager at GenOway S.A. He serves as Director of GenOway S.A. Dr. Fraichard served as the Chief Executive Officer of GenOway S.A. until October 18, 2017. Dr. Fraichard worked for five years on animal models at the ENS where he produced the first model of hypothyroidism and co-founded the Transgenetic Center. Dr. Fraichard earned his Ph.D. at the Ecole Normale Supérieure de Lyon in Molecular and Cellular Biology in 1997. Dr. Fraichard did an MBA (1998-1999) at the HEC business school (Paris, France).

CEO Compensation
  • Insufficient data for Alexandre to compare compensation growth.
  • Insufficient data for Alexandre to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team

Alexandre Fraichard

TITLE
Co-Founder
TENURE
0.3 yrs
Board of Directors

Christian Grenier

TITLE
Chairman

Alexandre Fraichard

TITLE
Co-Founder

Robert Claude Leon

TITLE
Representative Director
AGE
69

Olivier de Beauregard

TITLE
Representative Director
AGE
58

Soubeyran Denis

TITLE
Director
TENURE
3.5 yrs

André Tartar

TITLE
Director
TENURE
1.9 yrs

Laurent Fraisse

TITLE
Director
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess genOway's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. genOway has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

genOway S.A., a biotechnology company, engages in the development and sale of custom genetically-modified mouse, rat, and cellular models worldwide. The company provides technological solutions for transgenesis and model design. It produces custom mouse models, such as knockout (KO) and knockin (KI) mouse models; custom rat models; custom cell models; catalog models; and phenotyping for in vivo or in vitro studies. The company also provides patented homologous recombination technology for the generation of genetically modified rodent models; CRISPR/Cas9 nuclease systems for the KO and KI model creation; and FLEx, an inducible point mutation technology that allows scientists to induce the expression of a mutated gene or a reporter gene during the lifetime of the animal model. In addition, it offers tetracycline on/off systems to control gene expression; and internal ribosome entry site technology to generate multigenic-based disease models, reporter models, cell lineage tracking models, and tissue-specific Cre driver lines, as well as to monitor cell expression patterns in KO models. Further, the company provides recombinase-mediated cassette exchange technology to enable the swapping of genomic regions; and Quick Knockin technology, such as Rosa26, Hprt, and AAVS1. It serves pharmaceutical and life science companies, and academic institutes. genOway S.A. has a strategic alliance with Merck to develop and validate new CRISPR/Cas9-related products and solutions. The company was founded in 1999 and is based in Lyon, France.

Details
Name: genOway S.A.
JEH
Exchange: DB
Founded: 1999
€10,147,191
5,831,719
Website: http://www.genoway.com
Address: genOway S.A.
Technopark 2,
31 Rue Saint Jean de Dieu,
Lyon,
Rhône-Alpes, 69007,
France
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA ALGEN Common Stock Euronext Paris FR EUR 07. May 2007
DB JEH Common Stock Deutsche Boerse AG DE EUR 07. May 2007
Number of employees
Current staff
Staff numbers
106
genOway employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 21:25
End of day share price update: 2019/04/24 00:00
Last earnings filing: 2019/03/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.